Tag Archives: Michael Higgins

September 3, 2021   No comments

Forte Biosciences (FBRX) was Downgraded to a Hold Rating at Ladenburg Thalmann & Co.

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. downgraded Forte Biosciences (FBRX – Research Report) to Hold. The company’s shares closed last Thursday at $28.59, close to its 52-week low of $23.61. According to TipRanks.com, Higgins

Read More
July 19, 2021   No comments

Artelo Biosciences (ARTL) Gets a Buy Rating from Ladenburg Thalmann & Co.

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Artelo Biosciences (ARTL – Research Report) today and set a price target of $7.00. The company’s shares closed last Friday at $1.00. According to TipRanks.com, Higgins is a

Read More
March 26, 2021   No comments

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Knight Therapeutics (Other OTC: KHTRF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viridian Therapeutics (VRDN – Research Report) and Knight Therapeutics (KHTRF – Research Report) with bullish sentiments. Viridian Therapeutics (VRDN) Ladenburg Thalmann &

Read More
February 12, 2021   No comments

Artelo Biosciences (ARTL) Receives a Buy from Ladenburg Thalmann & Co.

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Artelo Biosciences (ARTL – Research Report), with a price target of $7.00. The company’s shares closed last Thursday at $1.63. According to TipRanks.com,

Read More
September 29, 2020   No comments

Forte Biosciences (FBRX) Gets a Buy Rating from Ladenburg Thalmann & Co.

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Forte Biosciences (FBRX – Research Report), with a price target of $70.00. The company’s shares closed last Tuesday at $49.00. According to TipRanks.com,

Read More
September 29, 2020   No comments

Palatin Technologies (PTN) Received its Third Buy in a Row

After H.C. Wainwright and Canaccord Genuity gave Palatin Technologies (NYSE MKT: PTN) a Buy rating last month, the company received another Buy, this time from Ladenburg Thalmann & Co. Analyst Michael Higgins maintained a Buy rating on Palatin Technologies today

Read More
« Older posts